Vanguard Group
SGYP

Vanguard Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Vanguard Group’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,168,848
Closed -$361K – 4144
2018
Q4 		$361K Sell
3,168,848
-18,856,745
-86% -$12.4M ﹤0.01% 3795
2018
Q3 		$37.4M Buy
22,025,593
+1,224,873
+6% +$2.19M ﹤0.01% 2292
2018
Q2 		$36.2M Buy
20,800,720
+416,710
+2% +$720K ﹤0.01% 2298
2018
Q1 		$37.3M Buy
20,384,010
+349,683
+2% +$739K ﹤0.01% 2218
2017
Q4 		$44.7M Buy
20,034,327
+2,013,173
+11% +$5M ﹤0.01% 2119
2017
Q3 		$52.3M Buy
18,021,154
+598,828
+3% +$2.04M ﹤0.01% 2026
2017
Q2 		$77.5M Buy
17,422,326
+1,636,563
+10% +$6.75M ﹤0.01% 1811
2017
Q1 		$73.6M Buy
15,785,763
+2,493,557
+19% +$14.5M ﹤0.01% 1812
2016
Q4 		$80.9M Buy
13,292,206
+709,345
+6% +$3.71M ﹤0.01% 1751
2016
Q3 		$69.3M Buy
12,582,861
+273,367
+2% +$1.28M ﹤0.01% 1779
2016
Q2 		$46.8M Buy
12,309,494
+5,500,297
+81% +$18.6M ﹤0.01% 1931
2016
Q1 		$18.8M Buy
6,809,197
+221,924
+3% +$804K ﹤0.01% 2328
2015
Q4 		$37.4M Buy
6,587,273
+116,566
+2% +$711K ﹤0.01% 2018
2015
Q3 		$34.3M Buy
6,470,707
+929,568
+17% +$7.19M ﹤0.01% 2045
2015
Q2 		$46M Buy
5,541,139
+310,465
+6% +$1.5M ﹤0.01% 1989
2015
Q1 		$24.2M Buy
5,230,674
+309,947
+6% +$1.01M ﹤0.01% 2246
2014
Q4 		$15M Buy
4,920,727
+101,226
+2% +$299K ﹤0.01% 2370
2014
Q3 		$13.4M Buy
4,819,501
+53,223
+1% +$193K ﹤0.01% 2369
2014
Q2 		$19.4M Buy
4,766,278
+247,306
+5% +$1.05M ﹤0.01% 2230
2014
Q1 		$24M Buy
4,518,972
+278,442
+7% +$1.56M ﹤0.01% 2127
2013
Q4 		$23.5M Buy
4,240,530
+88,457
+2% +$381K ﹤0.01% 2111
2013
Q3 		$18.7M Buy
4,152,073
+136,574
+3% +$612K ﹤0.01% 2134
2013
Q2 		$17.1M Buy
+4,015,499
New +$20.2M ﹤0.01% 2121

Other funds holding SGYP

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's SGYP Position: Q1 2019 in Review

Vanguard Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 3,168,848 shares — an estimated $361K sold.

Vanguard Group first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $80.9M in Q4 2016. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Vanguard Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • Vanguard Group sold 3,168,848 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $361K.
  • Vanguard Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
  • Vanguard Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $80.9M in Q4 2016.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Vanguard Group's 13F filing for Q1 2019, filed 15 May 2019.